{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T10:00:00Z","timestamp":1772791200143,"version":"3.50.1"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1097\/mbc.0b013e328364668a","type":"journal-article","created":{"date-parts":[[2013,8,14]],"date-time":"2013-08-14T17:44:13Z","timestamp":1376502253000},"page":"844-847","source":"Crossref","is-referenced-by-count":1,"title":["Number of metabolic syndrome risk parameters associated with TAFIa\/ai antigen levels"],"prefix":"10.1097","volume":"24","author":[{"given":"Fahri","family":"Gunes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erdem","family":"Akbal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehmet","family":"Asik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hacer","family":"Sen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emine","family":"Binnetoglu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murat","family":"Kizilgun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mustafa","family":"Ozbek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-8-20210203","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1161\/01.CIR.0000111245.75752.C6","article-title":"The American Heart Association, the National Heart, Lung, and Blood Institute: Definition of MetS: report of the National Heart, Lung, and Blood InstituteAmerican Heart Association conference on scientific issues related to definition.","volume":"109","author":"Grundy","year":"2004","journal-title":"Circulation"},{"key":"R2-8-20210203","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1055\/s-0037-1614029","article-title":"Plasma procarboxypeptidase U in men with symptomatic coronary artery disease.","volume":"84","author":"Silveira","year":"2000","journal-title":"Thromb Haemost"},{"key":"R3-8-20210203","doi-asserted-by":"crossref","first-page":"14477","DOI":"10.1074\/jbc.270.24.14477","article-title":"Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor.","volume":"270","author":"Bajzar","year":"1995","journal-title":"J Biol Chem"},{"key":"R4-8-20210203","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1001\/archinte.159.10.1104","article-title":"Clustering of metabolic factors and coronary heart disease.","volume":"159","author":"Wilson","year":"1999","journal-title":"Arch Intern Med"},{"key":"R5-8-20210203","doi-asserted-by":"crossref","first-page":"683","DOI":"10.2337\/diacare.24.4.683","article-title":"Cardiovascular morbidity and mortality associated with the metabolic syndrome.","volume":"24","author":"Isomaa","year":"2001","journal-title":"Diabetes Care"},{"key":"R6-8-20210203","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1161\/01.CIR.0000140762.04598.F9","article-title":"National Cholesterol Education Program versus World Health Organization Metabolic Syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study.","volume":"110","author":"Hunt","year":"2004","journal-title":"Circulation"},{"key":"R7-8-20210203","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1001\/archinte.164.10.1092","article-title":"Cardiorespiratory fitness attenuates the effects of the metabolic syndrome on all-cause and cardiovascular disease mortality in men.","volume":"164","author":"Katzmarzyk","year":"2004","journal-title":"Arch Intern Med"},{"key":"R8-8-20210203","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1161\/01.ATV.0000015445.22243.F4","article-title":"Plasma thrombin-activatable fibrinolysis inhibitor antigen concentration and genotype in relation to myocardial infarction in the north and south of Europe.","volume":"22","author":"Juhan Vague","year":"2002","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R9-8-20210203","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1182\/blood.V95.9.2855.009k02_2855_2859","article-title":"Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis.","volume":"95","author":"Van Tilburg","year":"2000","journal-title":"Blood"},{"key":"R10-8-20210203","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1080\/09513590802549874","article-title":"Thrombin activatable fibrinolysis inhibitor and other hemostatic parameters in patients with polycystic ovary syndrome.","volume":"25","author":"Oral","year":"2009","journal-title":"Gynecol Endocrinol"},{"key":"R11-8-20210203","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/MBC.0b013e3283009c69","article-title":"Fenofibrate improves endothelial function and decreases thrombin-activatable fibrinolysis inhibitor concentration in metabolic syndrome.","volume":"19","author":"Kilicarslan","year":"2008","journal-title":"Blood Coagul Fibrinol"},{"key":"R12-8-20210203","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1161\/01.ATV.0000199246.08616.98","article-title":"Development of ELISAs measuring the extent of TAFI activation.","volume":"26","author":"Ceresa","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R13-8-20210203","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.dsx.2012.05.017","article-title":"The reliability of the National Cholesterol Education Programs Adult Treatment Panel III(NCEPATP III) and the International Diabetes Federation (IDF) definitions in diagnosing metabolic syndrome (MetS) among Gaza Strip Palestinians.","volume":"6","author":"Sirdah","year":"2012","journal-title":"Diabetes Metab Syndr"},{"key":"R14-8-20210203","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1210\/jcem.87.2.8214","article-title":"Insulin resistance is associated with increased circulating level of thrombin-activatable fibrinolysis inhibitor in type 2 diabetic patients.","volume":"87","author":"Hori","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"R15-8-20210203","doi-asserted-by":"crossref","first-page":"210","DOI":"10.2174\/187221412802481748","article-title":"Role of thrombin activatable fibrinolysis inhibitor in endocrine and cardiovascular disorders: an update.","volume":"6","author":"Akinci","year":"2012","journal-title":"Recent Pat Endocr Metab Immune Drug Discov"},{"key":"R16-8-20210203","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.thromres.2011.10.031","article-title":"Thrombin activatable fibrinolysis inhibitor: at the nexus of fibrinolysis and inflammation.","volume":"129","author":"Colucci","year":"2012","journal-title":"Thromb Res"},{"key":"R17-8-20210203","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.2337\/diacare.28.9.2211","article-title":"MetS accompanied by hypercholesterolemia is strongly associated with proinflammatory state and impairment of fibrinolysis in patients with type 2 diabetes.","volume":"28","author":"Aso","year":"2005","journal-title":"Diabetes Care"},{"key":"R18-8-20210203","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.amjcard.2008.05.010","article-title":"Relation of the number of MetS risk factors with all-cause and cardiovascular mortality.","volume":"102","author":"Ho","year":"2008","journal-title":"Am J Cardiol"}],"container-title":["Blood Coagulation & Fibrinolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MBC.0b013e328364668a","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:31:49Z","timestamp":1620959509000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00001721-201312000-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":18,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/mbc.0b013e328364668a","relation":{},"ISSN":["0957-5235"],"issn-type":[{"value":"0957-5235","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12]]}}}